WASHINGTON — The Food and Drug Administration is in a precarious position as it heads toward 2026.
The agency has been mired by high-profile departures, feuds between top leaders, accusations of politicization, and low morale. It has lost thousands of employees to layoffs and resignations and cannot seem to hold onto a director of the drug center, which has been led by five different people since January.
Even the fate of Commissioner Marty Makary is up in the air. The personnel turmoil has caused concern among Health and Human Services and White House officials, according to Politico and The Wall Street Journal. These officials reportedly considered scaling back Makary’s responsibilities.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply